Clinical trials: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal.
- Conditions
- Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor
- Trial name
- NCT07416188
- Testing
- LMP744, Conventional Surgery or Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Glioblastoma (GBM)
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with…
- Trial name
- STAR-GBM (NCT07185880)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Relapsed Cancer, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol).
- Trial name
- GBrecurr (NCT06430424)
- Testing
- Relapsed glioblastoma
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Bordeaux
Glioblastoma
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
This is a Phase 1, single-arm MT-125 dose escalation study followed by a Phase 2, randomized parallel design dose expansion phase, to determine the safety and tolerability of MT-125 administered 5 consecutive days a week with 2…
- Trial name
- NOVA-GBM (NCT07604285)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed…
- Trial name
- GBM AGILE (NCT03970447)
- Testing
- Temozolomide, Lomustine, Regorafenib
- Where
- 63 sites in United States, Australia and 4 more
- Volunteers
- 2,250 people
- Sponsor
- Global Coalition for Adaptive Research
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastom WHO Grade 4
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.
- Trial name
- NCT07520214
- Testing
- mRNA vaccine: GV-907、GV-108
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Neurosurgical Institute
Glioblastoma, Recurrent Glioblastoma
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
- Conditions
- Glioblastoma, Recurrent Glioblastoma, Brain Tumor
- Trial name
- NCT06552260
- Testing
- Troriluzole
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Ugonma Chukwueke
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Study of Niacin in Glioblastoma
This is a single institution Phase I-II study to evaluate the tolerability and Maximum Tolerated Dose (MTD) (Phase I) and efficacy (Phase II) of adding Niacin CRT™ to standard first line treatment (concurrent Radiation Therapy…
- Trial name
- NCT04677049
- Testing
- Niacin CRT
- Where
- Canada
- Volunteers
- 59 people
- Sponsor
- AHS Cancer Control Alberta
Glioblastoma, Glioblastoma, IDH-wildtype
Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas
This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of…
- Conditions
- Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Trial name
- NCT07620548
- Testing
- NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Washington University School of Medicine
Astrocytoma, Grade IV, Glioblastoma
BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
The main purposes of this study are: I. To assess that the four habitats within the tumor (HAT and LAT) and edema (IPE and VPE) in high-grade glioma are different at vascular, tissular, cellular and molecular levels. II.
- Conditions
- Astrocytoma, Grade IV, Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype
- Trial name
- BIOhabitats (NCT05375318)
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Juan M Garcia-Gomez
Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain.
- Conditions
- Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
- Trial name
- NCT05864534
- Testing
- Balstilimab, Botensilimab, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Feasibility of ONCOhabitats for Surgical and Treatment Planning in IDH-Wildtype Glioblastoma (SINUE)
The goal of this clinical trial is to validate ONCOhabitats, an advanced imaging software, as a medical device for the clinical management of IDH-wildtype glioblastoma.
- Trial name
- SINUE (NCT07111195)
- Testing
- The ONCOhabitats software for MRI-based habitat segmentation
- Where
- 5 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Juan M Garcia-Gomez
Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.
- Conditions
- Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastoma Multiforme, Adult
- Trial name
- NCT07668869
- Testing
- Tumor Treating Fields (TTFields), FET-PET-Guided Stereotactic Radiosurgery
- Where
- Poland
- Volunteers
- 92 people
- Sponsor
- Prof. Franciszek Lukaszczyk Memorial Oncology Center
Glioblastoma, Adult-type Diffuse Gliomas
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating…
- Trial name
- FIGHT-209 (NCT05267106)
- Testing
- Pemigatinib
- Where
- 79 sites in United States, Denmark and 7 more
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma
Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
This is a 2-part multicenter Phase 1b study designed to test icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation design where different doses are examined.
- Conditions
- Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma, Glioblastoma Surgery
- Trial name
- Glio (NCT04782609)
- Testing
- Icapamespib
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Samus Therapeutics, Inc.
Glioma, Malignant
Niraparib and Temozolomide in Patients Glioblastoma
The study evaluates safety, tolerability, pharmacokinetics at recommended phase II dose (RP2D) and preliminary antitumor activity of Niraparib + dd-TMZ "one week on, one week off" in patients affected by recurrent GBM IDH…
- Trial name
- ONC-2022-001 (NCT06258018)
- Testing
- Temodal, Niraparib
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Armando Santoro, MD
Glioblastoma, IDH-wildtype, Glioblastoma
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of…
- Conditions
- Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Trial name
- NCT05879367
- Testing
- Eflornithine (Dose Level 1), Eflornithine (Dose Level 2), Eflornithine (Dose Level -1)
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Orbus Therapeutics, Inc.
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study
This prospective, interventional, monocentric study will aim at investigating the relationship between pesticide exposure and the treatment response of patients with GBM.
- Trial name
- EXPOGLIO (NCT07788430)
- Testing
- Biological sample collection, Self-reported questionnaire
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Claudius Regaud
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and…
- Trial name
- NCT05765812
- Testing
- Zedoresertib, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4)…
- Trial name
- GLIOMAX-101 (NCT07386002)
- Testing
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 40 people
- Sponsor
- T-MAXIMUM Pharmaceutical Inc